Why the study?
The optimal blood pressure goal in patients with diabetes mellitus remains controversial, and whether baseline blood pressure or cardiovascular disease risk influences the benefits and risks of intensified antihypertensive therapy is uncertain.
Does combination perindopril-indapamide reduce mortality and major vascular events in patients with type 2 diabetes mellitus at moderate-to-high cardiovascular risk, regardless of baseline blood pressure?
Does combination perindopril-indapamide reduce mortality and major vascular events in patients with type 2 diabetes mellitus at moderate-to-high cardiovascular risk, regardless of baseline blood pressure?
Intensive blood pressure lowering with perindopril-indapamide benefits patients with type 2 diabetes regardless of baseline blood pressure or cardiovascular risk, challenging guidelines that restrict treatment based on these thresholds.
Answers are grounded in this paper and cite their sources.
May support risk-stratified BP targets in diabetes; leaves open optimal thresholds pending dedicated trials.
The optimal blood pressure (BP) goal in patients with diabetes mellitus remains controversial. We examined whether benefits and risks of intensified antihypertensive therapy in diabetes mellitus are influenced by either baseline BP or cardiovascular disease (CVD) risk. We studied 10 948 people with diabetes mellitus, at moderate-to-high risk, in the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation). Cox models were used to determine whether baseline BP category or CVD risk modified the outcomes of combination perindopril-indapamide treatment, compared with placebo. During 4.3 years of follow-up, treatment with perindopril-indapamide versus placebo reduced mortality and major vascular (macrovascular or microvascular) events. There was no evidence of differences in these effects, regardless of baseline systolic BP (evaluated down to <120 mm Hg; P for heterogeneity, 0.85), diastolic BP (evaluated down to <70 mm Hg; P=0.49), or whether 10-year CVD risk was ≥20% or <20% ( P=0.08). The effects of randomized treatment on discontinuation of treatment because of cough or hypotension/dizziness were also statistically consistent across subgroups defined by baseline BP and CVD risk (all P ≥0.08). Adults with diabetes mellitus appear to benefit from more intensive BP treatment even at levels of BP and CVD risk that some guidelines do not currently recommend for intervention. Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT00751972.
No takes yet. Share an insight, caveat, or question.
Rahman et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: